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Abstract. Little is known about the clinical features and outcomes of SARS-CoV-2 infection in Africa.We conducted a
retrospective cohort study of patients hospitalized for COVID-19 between March 10, 2020 and July 31, 2020 at seven
hospitals in Kinshasa, Democratic Republic of the Congo (DRC). Outcomes included clinical improvement within 30 days
(primary) and in-hospital mortality (secondary). Of 766 confirmedCOVID-19 cases, 500 (65.6%)weremale, with amedian
(interquartile range [IQR]) age of 46 (34–58) years. One hundred ninety-one (25%) patients had severe/critical disease
requiring admission in the intensive care unit (ICU). Six hundred twenty patients (80.9%) improved and were discharged
within 30daysof admission.Overall in-hospitalmortalitywas13.2% (95%CI: 10.9–15.8), andalmost 50%among those in
the ICU. Independent risk factors for death were age < 20 years (adjusted hazard ratio [aHR] = 6.62, 95%CI: 1.85–23.64),
40–59 years (aHR = 4.45, 95% CI: 1.83–10.79), and ³ 60 years (aHR = 13.63, 95% CI: 5.70–32.60) compared with those
aged 20–39 years, with obesity (aHR = 2.30, 95% CI: 1.24–4.27), and with chronic kidney disease (aHR = 5.33, 95% CI:
1.85–15.35). In marginal structural model analysis, there was no statistically significant difference in odds of clinical
improvement (adjusted odds ratio [aOR] = 1.53, 95% CI: 0.88–2.67, P = 0.132) nor risk of death (aOR = 0.65, 95% CI:
0.35–1.20) when comparing the use of chloroquine/azithromycin versus other treatments. In this DRC study, the high
mortality among patients aged < 20 years and with severe/critical disease is of great concern, and requires further
research for confirmation and targeted interventions.
INTRODUCTION
SARS-CoV-2 infection and COVID-19 arrived later in sub-
Saharan Africa (SSA) than in most other regions of the world.
Asof August 26, 2020, therewere 1,014,834 cases and20,787
deaths (2.1% case fatality rate [CFR]) in the WHO African
Region.1 The high numbers of cases and deaths expected in
SSA have not been witnessed to date, despite relatively weak
health systems and other barriers limiting comprehensive
implementation of public health interventions.2 Several ex-
planations have been hypothesized for this unexpected find-
ing, including early lockdowns, low SARS-CoV-2 testing
capacity, a younger population, and concomitant cross-
immunity from parasitic diseases and other circulating
coronaviruses.3–6
The Democratic Republic of the Congo (DRC) confirmed its
first COVID-19 case on March 10, 2020 and within 2 weeks
declared a state of emergency that included travel bans,
lockdowns, widespread testing, and quarantine.6 As of Au-
gust 26, 2020, the DRC has reported 9,891 COVID-19 cases
and 251 deaths (2.5% CFR), with the capital city Kinshasa
being the epicenter. With increased testing, more COVID-19
casesarebeing reported inSSA,3–5butdataonsociodemographic/
clinical characteristics and outcomes among hospitalized
patients are still scanty. It is important to ascertain whether
features of COVID-19 in Africa differ from those in non-African
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countries.7,8 Furthermore, in SSA, there are little data on the
prevalence of SARS-CoV-2 coinfection or comorbidity with
noncommunicable diseases (NCDs) (e.g., hypertension, di-
abetes, and obesity) and communicable diseases (e.g., HIV,
tuberculosis [TB], and malaria), which may influence COVID-
19 presentations and outcomes.9,10 We aimed to describe
clinical characteristics, laboratory features, and outcomes of
hospitalized patients with COVID-19 in DRC and to differen-
tiate them from other non-African populations.
METHODS
Study design, study population, and criteria for hospital
admission. We conducted a cohort analysis using routinely
collected data from the DRC Ministry of Health’s COVID-19
Multi-Sectoral Response Committee database, spanning
March 10, 2020–July 31, 2020. All COVID-19 patients admit-
ted at the seven largest health facilities in Kinshasa (one pri-
vate, two faith-based Catholic, and four public) were eligible
for inclusion. Patients were staged according to the WHO
COVID-19 clinical categories of mild, moderate, severe, and
critical disease (Supplemental Table 1).11 The decision to
hospitalize patients was based on signs or symptoms of
moderate/severe disease, comorbidities, pregnancy, or the
development of complications in cases initially managed at
home.
Predictors and outcomes variables. Using standardized
data collection forms, we extracted sociodemographic, clini-
cal (including comorbidities), laboratory, COVID-19 treatment,
and current medication data. Outcomes of interest were
clinical improvement within 30 days (primary) and in-hospital
mortality (secondary).
SARS-CoV-2 RT-PCR testing. Oropharyngeal or nasal
samples were processed at the Virology Laboratory of the
National Institute for Biomedical Research in Kinshasa.
Samples were tested for SARS-CoV-2 RNA by either BGI RT-
PCR using the ABI 7500 Fast Applied Biosystems instrument
(Thermo Fisher Scientific, Waltham, MA) or Xpert Xpress
SARS-CoV-2 using the GeneXpert platform (Cepheid, Sun-
nyvale, CA), following the manufacturers’ instructions.
Casemanagement procedures.On admission, a detailed
history, physical examination, including pulse oximetry, was
performed. Self-reported HIV and TB status was further cor-
roborated on admission with a review and confirmation of
documented medical record information on relevant medica-
tions and/or care for these coinfections. The samewas carried
out for patients self-reporting NCD comorbidities (e.g., hy-
pertension anddiabetes). Patientswere treatedwith symptom
management, supplemental oxygen, and compassionate
treatment protocols according to national guidelines in effect
at the time.12 Mild cases were treated with hydroxy-
chloroquine (HCQ)/chloroquine (CQ) + azithromycin (AZ), and
moderate cases were treated with HCQ/CQ + AZ (Option 1)
or lopinavir/ritonavir (LPV/r) (Option 2) + enoxaparin (pro-
phylactic low–molecularweight heparin).10 Severe caseswere
treatedwithHCQ/CQ+AZ+ third-generation cephalosporin +
enoxaparin and assisted ventilation (Option 1), or remdesivir +
third-generation cephalosporin + enoxaparin + vitamin C and
assisted ventilation (Option 2), or HCQ/CQ + (LPV/r) + third-
generation cephalosporin + enoxaparin + dexamethasone
and assisted ventilation (Option 3).12 As of August 24, 2020,
remdesivir has not yet been licensed in the DRC, and not all
patients received all indicated treatments because of lack of
availability.
Statistical analysis.We summarized baseline demographic
and clinical characteristics using frequencies and proportions
by clinical stage at presentation. Continuous variables were
summarized using medians (IQR). Chi-square tests were used
to compare proportions and Wilcoxon rank-sum tests to
compare medians between mild/moderate and severe/critical
cases. COVID-19 symptom resolution was assessed by com-
paring proportions of patients with symptoms at day 1 (day of
admission) versus 10 days later, using the chi-square test for
marginal homogeneity. Laboratory values were compared at
day 1 and day 10 using the Wilcoxon signed-rank test.
We estimated the proportion of patients with clinical im-
provement, stratified by baseline demographic and clinical
characteristics. Factors associated with clinical improvement
at P-value < 0.1 in unadjusted univariable logistic regression
were included in a multivariable logistic regression model to
identify independent factors associated with clinical im-
provement. The strength of the association was expressed as
adjusted odds ratios and accompanying 95% CIs. Similarly,
we estimated the hazard of death stratified by baseline char-
acteristics and identified factors independently associated
with death using Cox regression. The final regression model
was performed after the proportionality of hazards assump-
tion was confirmed by a nonsignificant global test and
Schoenfeld residuals with horizontal tendency, as well as the
presence of parallelism in the In½InðSðtÞÞ plot.
We summarized the strength of association between fac-
tors and death using adjusted hazard ratios and associated
95% CIs. We used a marginal structural model (MSM) based
on inverse probability of treatment weighting (IPTW) to assess
the efficacy of the CQ + AZ combination versus other therapy,
with death as the outcome. Gender, age, WHO stage of dis-
ease at admission, hypertension, diabetes mellitus, asthma/
chronic obstructive pulmonary disease (COPD), heart dis-
ease, chronic kidney disease (CKD), HIV, TB, obesity, and
cancer were included in the treatment model as potential
confounders. All analyses were performed using Stata soft-
ware version 16.1 (College Station, TX). The Venn diagram
illustrations of comorbidities and their combination were
completed in R Studio Version 1.3.959, May 2020 (R Studio
Inc., Boston, MA).13
Regulatory approvals. The study was approved by the
University of Kinshasa School of Public Health’s Ethics
Committee (NESP/CE/114/2020 – July 17, 2020); the In-
stitutional Review Board of the University of Pittsburgh, PA
(STUDY20080174); and the DRC’s National COVID-19 Multi-
Sectorial Response Committee and National Institute of Bio-
medical Research.
RESULTS
Sociodemographic and clinical characteristics of hos-
pitalized confirmed cases. Of 852 confirmed COVID-19
cases admitted, we analyzed 766 (89.9%) with complete in-
formation (Figure 1). Baseline sociodemographic character-
istics and clinical stage did not differ between patients who
were excluded and included in the analysis (Supplemental
Table 2). Table 1 summarizes patient characteristics at ad-
mission by disease severity. The median (IQR) age was 46
(34–58) years, with 23.3% aged ³ 60 years. Thirty-four (4.5%)
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patients were < 20 years, with a median age (IQR) of 14.5
(7–18) years and 11 (32%) younger than 10 years. Five hun-
dred (65.3%) patients were male. Among the 262 females
admitted, 12 (4.6%)were pregnant. At admission, 468 (61.1%)
patients hadmild, 107 (14.0%)moderate, 164 (21.4%) severe,
and 27 (3.5%) critical disease. All 191 patients with severe or
critical disease (25% of total) were admitted to the intensive
careunit (ICU). Among510patientswithSpO2measurements,
38.2% had SpO2 £ 90% on room air. Four of the 34 children
presented with severe or critical disease. Compared with
those with mild/moderate COVID-19, severe/critical patients
had higher median (IQR) C-reactive protein: 60 mg/dL
(48.0–192.0) versus 24.0 mg/dL (2.6–54.0), respectively (P =
0.010), and median (IQR) D-dimer levels (ng/mL): 342.5
(246.0–443.0) versus 6.9 (2.8–100.0), respectively (P = 0.011).
Among 764 patients with baseline comorbidity information,
264 (34.6%) reported at least one comorbidity, with 128
(48.5%) having more than one comorbidity (Figure 2). The
most prevalent comorbidities were hypertension (25.4%) and
diabetes (14.0%). Self-reported prevalence of obesity was
5.1%, heart disease 3.9%, asthma/COPD 3.4%, CKD 0.9%,
active TB 2.5%, and HIV 1.6%. Patients with severe/critical
disease were older and had a higher prevalence of hyperten-
sion, heart disease, obesity, diabetes, asthma/COPD, and
poorer SpO2 levels than those with mild/moderate disease
(Table 1). The majority of patients (n = 630, 86.8%) were
treatedwithCQ/AZ. Eighteenpatients of 545 (3.1%)onCQ/AZ
versus 1/67 (1.5%) on other regimens reported at least one
side effect (P = 0.70), including pruritus, skin rash, gastroin-
testinal upset, palpitations, or bradycardia. Overall, 620 pa-
tients (80.9%) improved and were discharged within 30 days;
101 (13.2%) died, and 20 (2.6%) were transferred to home
care. Median hospital stay among recovered patients was 13
(IQR: 9–17) days. Of the 12 pregnant women, three pre-
sented with severe/critical disease and nine had mild/
moderate disease. Five had comorbidities (one hyperten-
sion and obesity, one asthma, and three TB). All 12 pregnant
women recovered and were discharged in 30 days. Four
children (11.8%) died; they were 16-, 17-, 17-, and 19-year-
olds. Three of four had severe/critical disease (severe
pneumonia), and one hadmoderate disease (pneumonia) at
admission.
Clinical and respiratory parameters at days 1 and 10 of
hospitalization. Supplemental Table 3 presents the changes
in markers of infection among patients with assessments at
day 1 and day 10. The proportion reporting headaches (23.2%
versus 0.6%, respectively, P < 0.001), fever (39.8% versus
0.3%, P < 0.001), cough (40.9% versus 1.5%,P < 0.001), sore
throat (12.0% versus 0.8%, P < 0.001), rhinorrhea (9.3% ver-
sus 0.1%, P < 0.001), and dyspnea (37.8% versus 1.0%, P <
0.001) decreasedmarkedly betweenday1andday10.Median
oxygen saturation levels significantly improved from 89% to
98% over the same time interval.
Factors associated with clinical improvement. The ad-
justedmodel for clinical improvement included age-group, the
presence of comorbidities (hypertension, heart disease, di-
abetes, obesity, CKD, and cancer) and treatment received.
Table 2 shows factors independently associated with clinical
improvement during the observation time. Patients aged
20–39 years (aOR = 9.40, 95%CI: 4.78–18.52) or 40–59 years
(aOR = 2.64, 95% CI: 1.64–4.26) were more likely to improve
than patients ³ 60 years. Patients with obesity (aOR = 0.27,
95%CI: 0.12–0.59) were less likely to improve than nonobese
patients. Adjusting for treatment with CQ/AZ and age-group,
the odds of clinical improvement among patients with severe/
critical COVID-19 was 87% lower than among that with mild/
moderate disease (aOR = 0.13, 95% CI: 0.08–0.20). In MSM
analysis, there was no statistically significant difference in
odds of clinical improvement (aOR = 1.53, 95%CI: 0.88–2.67,
P = 0.132) when comparing the use of CQ/AZ versus other
treatment regimens.
Factors associatedwith in-hospitalmortality.Overall, in-
hospitalmortalitywas13.2% (95%CI: 10.9–15.8). Themedian
time between admission and death was 4 days (IQR: 2–5).
There were no significant gender differences in mortality
(13.0%females versus13.4%males).Morepatients aged³60
years (32.0%) died, compared with those < 60 years (7.5%)
(P< 0.001) (Table 3, Figure 3). In-hospitalmortality was greater
among patients with severe/critical disease than patients with
mild/moderate disease (45.0% versus 2.6%, respectively, P <
0.001). Patients < 20 years (aHR = 6.62, 95% CI: 1.85–23.64),
40–59 years (aHR = 4.45, 95%CI: 1.83–10.79), and ³ 60 years
(aHR = 13.63, 95% CI: 5.70–32.60) had significantly higher
hazards of death than those aged 20–39 years. Significantly
FIGURE 1. Study flow chart.
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TABLE 1
Demographics and clinical and laboratory characteristics (N = 766)
Characteristic All patients (n = 766) Severe patients (severe and critical) (n = 191) Non-severe patients (mild and moderate) (n = 575) P-value
Age median (years) (IQR) 46 (34–58) 58 (44–66) 42 (32–54) < 0.001
Age-group (years), n (%)
< 20 34 (4.5) 4 (2.1) 30 (5.2) < 0.001
20–39 248 (32.5) 31 (16.2) 217 (37.9) –
40–59 303 (39.7) 67 (35.1) 236 (41.3) –
³ 60 178 (23.3) 89 (46.6) 89 (15.6) –
Gender, n (%)
Male 500 (65.6) 135 (71.1) 365 (63.8) 0.078
Female 262 (34.4) 55 (28.9) 207 (36.2) –
Missing 4 1 3 –
Hypertension, n (%)
Yes 194 (25.4) 87 (45.6) 107 (18.7) < 0.001
No 570 (74.6) 104 (54.4) 466 (81.3) –
Missing 2 0 2 –
Heart disease, n (%)
Yes 30 (3.9) 21 (11.1) 9 (1.6) < 0.001
No 733 (96.1) 169 (88.9) 564 (98.4) –
Missing 3 1 2 –
Obesity, n (%)
Yes 39 (5.1) 22 (11.5) 17 (3.0) < 0.001
No 725 (94.9) 169 (88.5) 556 (97.0) –
Missing 2 0 2 –
Diabetes, n (%)
Yes 107 (14.0) 60 (31.6) 47 (8.2) < 0.001
No 656 (86.0) 130 (68.4) 526 (91.8) –
Missing 3 1 2 –
Asthma/chronic obstructive
pulmonary disease, n (%)
Yes 26 (3.4) 12 (6.3) 14 (2.4) 0.011
No 738 (96.6) 179 (93.7) 559 (97.6) –
Missing 2 0 2 –
Chronic kidney disease, n (%)
Yes 7 (0.9) 3 (1.6) 4 (0.7) 0.375
No 759 (99.1) 188 (98.4) 571 (99.3) –
Cancer, n (%)
Yes 5 (0.6) 3 (1.6) 2 (0.4) 0.102
No 761 (99.4) 188 (98.4) 573 (99.6) –
Pregnancy among females, n
(%)
Yes 12 (4.6) 3 (5.4) 9 (4.4) 0.720
No 250 (95.4) 52 (94.6) 198 (95.6) –
SpO2, n (%)
< 90% 195 (38.2) 166 (92.2) 29 (8.8) < 0.001
³ 90% 315 (61.8) 14 (7.8) 301 (91.2) –
Missing 256 11 245 –
HIV positive, n (%)
Yes 12 (1.6) 3 (1.6) 9 (1.6) 1.000
No 752 (98.4) 188 (98.4) 564 (98.4) –
Missing 2 0 2 –
Current tuberculosis, n (%)
Yes 19 (2.5) 4 (2.1) 15 (2.6) 0.795
No 745 (97.5) 187 (97.9) 558 (97.4) –
Missing 2 0 2 –
SpO2 (median, IQR), N 89.0 (85–98) 510 79 (66–87) 180 98(95–99) 330 < 0.001
Blood glucose (median, IQR)
(mg/dL), N
105 (23–182) 33 25 (14.5–167.5) 16 131 (103–182) 17 0.031
Serum C-reactive protein
(median, IQR) (mg/dL), N
32 (3.3–60) 37 60 (48–192) 7 24 (2.6–54) 30 0.010
Serum potassium (median, IQR)
(mEq/L), N
3.9 (3.4–4.3) 17 4.3 (2.9–4.8) 3 3.9 (3.4–4.0) 14 0.488
Blood urea nitrogen, median
(mg/dL), N
32.5 (21.0–52.0) 46 49.7 (41.0–63.0) 14 23.1 (20.0–42.2) 32 0.002
Serum creatinine, (mg/dL), N 1.0 (0.9–1.2) 48 1.2 (1.0–2.0) 13 1.0 (0.8–1.1) 35 0.008
Plasma D-dimer (median, IQR)
(ng/mL), N
183 (6.87–349) 11 342.5 (246–443) 6 6.9 (2.8–100) 5 0.011
Electrocardiogram, n (%)
Normal 15 (20.6) 1 (2.7) 14 (38.9) < 0.001
Abnormal 58 (79.4) 36 (97.3) 22 (61.1) –
Missing 693 154 539 –
Chloroquine + azithromycin 630 (86.8) 152 (80.8) 478 (88.8) 0.005
Other* 96 (13.2) 36 (19.2) 60 (11.2) –
Missing 24 2 4 –
* Third-generation cephalosporin and/or amoxicillin +clavulanic acid and/or lopinavir/ritonavir and/or dexamethasone and/or azithromycin.
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more patients with comorbidities died than those without
comorbidities. Among the four children who died, one had
diabetes and hypertension and the rest had no comorbidities.
Mortality among patients with diabetes was greater than
nondiabetics (27.1% versus 10.8%, respectively, P < 0.001).
More obese versus nonobese patients died (43.6% versus
11.4%,P < 0.001). The hazard of death among obese patients
wasmore than double than that for nonobese patients (aHR =
2.30, 95%CI: 1.24–4.27). Compared with those without CKD,
patientswithCKDwere at a higher risk of death (57.1%versus
12.8,P< 0.001), with amore than 5-fold increase in the hazard
of death (aHR = 5.33, 95% CI: 1.85–15.35). Patients who re-
ceivedCQ/AZhad significantly lowermortality than thosewho
did not receive these drugs (11.0% versus 29.2%, re-
spectively, P < 0.001). Mortality in patients receiving supple-
mental oxygenwasgreater than that among thosewhodid not
(37.6% versus 2.1%, respectively, P < 0.001). Patients who
received CQ/AZ had a 74% reduction in hazard of death
compared with those who did not receive CQ/AZ (aHR = 0.26,
95% CI: 0.16–0.42). However, in MSM analysis, there was no
statistically significant difference in risk of death (aOR = 0.65,
95%CI: 0.35–1.20, P = 0.166) when comparing use of CQ/AZ
versus other treatment regimens.
DISCUSSION
This study is among the first to report clinical characteristics
and outcomes of hospitalizedCOVID-19 patients in an African
country. In this hospitalized Congolese cohort, ∼4.5% of pa-
tients were children < 20 years, which is similar to studies from
China,14 Europe,15 and the United States16 that have reported
between 1% and 5% of infections in children. Given that
SARS-CoV-2 testing is more frequently prompted by
symptoms and children typically have asymptomatic or mild
infection, the frequency of SARS-CoV-2 infection in Con-
golese children is likely to be higher than 5%.17 Similar to
Asian and Western cohorts, we observed male gender pre-
ponderance and previously reported presenting symptoms,
including cough, fever, dyspnea, headache, sore throat, and
rhinorrhea.18 Age and cardiometabolic comorbidities were
associated with more severe forms of COVID-19 at admission
and a higher risk of death. Unlike other reports, anosmia and
dysgeusia were not documented in our cohort. Not surpris-
ingly, patients admitted with severe COVID-19 were more
likely to require oxygen therapy; these patients also differed
from those with milder COVID-19 in terms of higher levels of
inflammatory markers.
In-hospital mortality was 13.2% in our study population.
Global estimates of in-hospitalmortality fromCOVID-19 range
between 15% and 20%, with up to 40% of hospitalized pa-
tients requiring intensive care.18 In Western countries, people
of African descent and other racial minorities are at increased
risk of worse clinical outcomes.19 In a recent U.S. cohort, age
and proportion of inpatients with comorbidities were higher
than our those in the Congolese cohort: mean age: 54 versus
48 years; hypertension: 44% versus 30%; diabetes: 39%
versus 16%; obesity: 35% versus 3.8%; respectively.20 Fur-
thermore, our overall in-hospital mortality rate (13.2%) may
have been influenced by hospitalization of patients with mild
disease who may been admitted because of inadequate care
and isolation at home due to overcrowding and/or poverty.
However, in-hospital mortality was greater among patients
with severe/critical disease than among patients those with
mild/moderate disease (45.0% versus 2.6%, respectively, P <
0.001), which is higher than Western reports20 but similar to
the ∼50%mortality of patients requiring admission to the ICU
in a South African cohort.21 Of note, dexamethasone has re-
cently been shown to reduce mortality by one-third among
seriously ill COVID-19 patients requiring oxygen or respiratory
support. The drug was introduced in the DRC’s national
COVID-19 treatment guidelines12 only from July 2020 (last
month of our study period), soon after the U.K. Recovery Trial
Press Release.22 Therefore, further evaluation is needed to
ascertain whether in-ICU mortality will decrease with the use
of dexamethasone in the DRC.
FIGURE 2. Venn diagram showing overlapping between the main
comorbidities among COVID-19 hospitalized patients. Patients with
chronic kidney disease (CKD) (n=7) and thosewith cancer (n=4)were
not included in the Venn diagram because of the limitation of the
package for amaximumof seven comorbidities. Of the seven patients
with CKD, three had concomitant hypertension and diabetes (n = 3),
DM (n = 3), and HTN (n = 1). Among the four patients with cancer, one
had concomitant heart disease.
FIGURE 3. Cumulative hazard of death over time stratified by age-
group. The steps in the graph indicate points at which patients died.
Patients dischargedwere censored at time of discharge. The time axis
extends to 80 days because that is the longest a patient stayed in
hospital.
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Among the comorbidities evaluated, hypertension and di-
abetes were clearly associated withmore severe presentation
andpoorer prognosis forCOVID-19. This is in linewith findings
published from China, the United States, and Europe.14–16
These two comorbidities were strongly co-prevalent in our
cohort, with 38% of hypertensive patients being diabetic, and
70% of diabetics being hypertensive. More importantly, de-
spite the overall prevalence of self-reported obesity being low
(potentially conservative bias due to underestimation), obesity
was a significant independent predictor of mortality. Early studies
suggest that cytokine release is central to the development of
COVID-19–related respiratory distress,20 that interleukin-6 (IL-6) is
produced bymultiple cells including adipocytes,23,24 and that IL-6
levels are elevated in obese individuals.25,26 Furthermore, adipose
tissue has been hypothesized to be a site for SARS-CoV-2 repli-
cation and shedding.27
In the French Coronavirus SARS-CoV-2 and Diabetes
Outcomes (CORONADO) study, among diabetic inpatients
with COVID-19, bodymass index and poor long-term glucose
control were independently associated with mechanical ven-
tilation and/or death.28 Several arguments suggest that there
is no causal link between severe pneumonia and chronic hy-
perglycemia and that the overrepresentation of diabetic pa-
tients with COVID-19 in ICUs indirectly reflects the impact of
obesity.29 Furthermore, higher hemoglobin A1c (HbA1c) at
admission does not appear to worsen COVID-19 prognosis in
type II diabetes.30 For this study, there were no HbA1c data
available; thus, we were unable to analyze its potential asso-
ciation with COVID-19 outcomes. We also found that CKD
was an independent risk factor for mortality, as reported from
outside Africa.31–34 Patients presenting with SARS-CoV-2
infection have shown varying degrees of renal dysfunction,
including a high incidence of acute kidney injury.32,35 A recent
study reported that the human kidney may be a unique target
for SARS-CoV-2 because it expresses angiotensin-converting
enzyme-2 surface receptors.32,33,35
There was no significant difference in mortality when com-
paring CQ/AZ versus other regimens by MSM analysis. Our
TABLE 2
Logistic regression of factors associated with clinical improvement within 30 days (N = 766)
Characteristic Improved, n (%) Unadjusted odds ratio (95% CI) Adjusted odds ratio (95% CI) P-value
Gender
Female (n = 262) 211 (80.5) 1 – –
Male (n = 500) 406 (81.2) 1.04 (0.71–1.52) – –
Age-group (years)
< 20 (n = 34) 29 (85.3) 3.58 (1.32–9.71) 2.98 (1.05–8.49) 0.041
20–39 (n = 248) 233 (94.0) 9.60 (5.25–17.55) 9.40 (4.77–18.52) < 0.001
40–59 (n = 303) 246 (81.9) 2.67 (1.76–4.05) 2.64 (1.64–4.26) < 0.001
³ 60 (n = 178) 110 (61.8) 1 1 –
Clinical stage at presentation
Mild or moderate (n = 575) 525 (91.3) 1 – –
Severe or critical (n = 191) 95 (49.7) 0.09 (0.06–0.14) – –
Hypertension
No (n = 570) 480 (84.2) 1 1 –
Yes (n = 194) 139 (71.6) 0.47 (0.32–0.70) 1.28 (0.76–2.18) 0.356
Heart disease
No (n = 733) 600 (81.9) 1 1 –
Yes (n = 30) 18 (60.0) 0.33 (0.16–0.71) 0.81 (0.32–2.03) 0.656
Diabetes
No (n = 656) 547 (83.4) 1 1 –
Yes (n = 107) 71 (66.4) 0.39 (0.25–0.62) 0.76 (0.43–1.35) 0.351
Obesity
No (n = 725) 600 (82.8) 1 1 –
Yes (n = 39) 19 (48.7) 0.20 (0.10–0.38) 0.27 (0.12–0.59) 0.001
Asthma/chronic obstructive pulmonary
disease
No (n = 738) 600 (81.3) 1 – –
Yes (n = 26) 19 (73.1) 0.62 (0.26–1.51) – –
Chronic kidney disease
No (n = 759) 617 (81.3) 1 1 –
Yes (n = 7) 3 (42.9) 0.17 (0.04–0.78) 0.22 (0.04–1.08) 0.063
Cancer
No (n = 761) 618 (81.2) 1 1 –
Yes (n = 5) 2 (40) 0.15 (0.02–0.93) 0.38 (0.06–2.50) 0.313
HIV
No (n = 752) 611 (81.2) 1 – –
Yes (n = 12) 8 (66.7) 0.46 (0.14–1.55) – –
Current tuberculosis
No (n = 745) 604 (81.1) 1 – –
Yes (n = 19) 15 (79.0) 0.88 (0.29–2.68) – –
Chloroquine/azithromycin-based
treatment vs. other
No (n = 96) 62 (64.6) 1 1 –
Yes (n = 630) 526 (83.5) 2.77 (1.74–4.43) 3.62 (2.12–6.16) < 0.001
Received oxygen
No (n = 330) 307 (93.0) 1 – –
Yes (n = 245) 137 (55.9) 0.10 (0.06–0.16) – –
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data do not conclusively exclude a CQ/AZ treatment effect,
given the lack of a comparator arm, and nonrandom treatment
allocation. However, recently published placebo-controlled
trials from the United States,36 the United Kingdom,37 and
Brazil38 have shown no effect of CQ or CQ/AZ on COVID-19
mortality. There is an urgent need for rigorous evaluation of
other promising and scalable cost-effective therapeutic op-
tions for the DRC and other African countries.
Our findings showed no association of HIV and/or TB with
baseline COVID-19 disease severity or prognosis. However,
definitive conclusions cannot be made because of low preva-
lence of HIV (1.6%) and active TB (2.2%) in our cohort. A
population-based U.K. study found that HIV-positive individuals
had more than double the risk of COVID-19–related mortality
than HIV-uninfected individuals after controlling for known con-
founding factors.39 Similarly, a retrospective analysis of > 20,000
South African adults with COVID-19 showed that HIV was as-
sociated with a doubling of COVID-19 mortality risk, although
thismay be an overestimate because of residual confounders.40
Larger SSA cohort studies are required to further define the
epidemiological, clinical, and risk relationships among the
overlapping epidemics of COVID-19, HIV, TB, and malaria.
Of great concern is that children and adolescents < 20 years
hadaCFRof 11.8%andwerenearly seven timesmore likely to
die than patients aged 20–39 years. By contrast, studies
mostly from China report CFRs of < 1% among both symp-
tomatic and asymptomatic, but mostly hospitalized
children.41,42 A recent U.S. study reported a CFR of 2%
among children hospitalized with COVID-19).43 All four pedi-
atric deaths in our DRC cohort occurred among older children
aged 16–19 years. Three of the four had severe/critical dis-
ease, and one hadmoderate disease at admission; also, three
of these four cases had no underlying comorbidity. Webb
et al.44 recently reported on 23 South African children with
MIS-C, among whom 52% required ICU admission primarily
because of cardiac dysfunction. There were no deaths re-
ported in this South African cohort; all the children survived.
Multisystem inflammatory syndrome was not specifically
TABLE 3
Cox regression of factors associated with hazard of death (N = 766)
Characteristic Died, n (%) Unadjusted hazards ratio (95% CI) Adjusted hazards ratio (95% CI)* P-value
Gender
Female (n = 262) 34 (13.0) 1 – –
Male (n = 500) 67 (13.4) 1.03 (0.68–1.56) – –
Age-group (years)
< 20 (n = 34) 4 (11.8) 5.10 (1.44–18.09) 6.62 (1.85–23.65) 0.004
20–39 (n = 248) 6 (2.4) 1 1 –
40–59 (n = 303) 34 (11.2) 4.62 (1.94–11.01) 4.45 (1.83–10.79) 0.001
³ 60 (n = 178) 57 (32.0) 14.85 (6.40–34.46) 13.63 (5.70–32.60) < 0.001
Clinical stage at admission
Mild or moderate (n = 575) 15 (2.6) 1 – –
Severe or critical (n = 191) 86 (45.0) 20.84 (12.02–36.14) – –
Hypertension
No (n = 570) 56 (9.8) 1 1 –
Yes (n = 194) 44 (22.7) 2.32 (1.56–3.45) 1.00 (0.62–1.61) 0.986
Heart disease
No (n = 733) 89 (12.1) 1 1 –
Yes (n = 30) 11 (36.7) 3.52 (1.88–6.60) 1.40 (0.68–2.88) 0.364
Diabetes
No (n = 656) 71 (10.8) 1 1 –
Yes (n = 107) 29 (27.1) 2.53 (1.64–3.91) 1.10 (0.66–1.81) 0.720
Obesity
No (n = 725) 83 (11.4) 1 1 –
Yes (n = 39) 17 (43.6) 3.87 (2.86–6.56) 2.30 (1.24–4.27) 0.009
Asthma/chronic obstructive pulmonary
disease
No (n = 738) 96 (13.0) 1 – –
Yes (n = 26) 4 (15.4) 1.27 (0.46–3.45) – –
Chronic kidney disease
No (n = 759) 97 (12.8) 1 1 –
Yes (n = 7) 4 (57.1) 5.33 (1.96–14.52) 5.33 (1.85–15.35) 0.002
Cancer
No (n = 761) 99 (13.0) 1 –
Yes (n = 5) 2 (40.0) 3.90 (0.96–15.82) – –
HIV
No (n = 752) 98 (13.0) 1 – –
Yes (n = 12) 2 (16.7) 1.23 (0.30–4.99) – –
Current tuberculosis
No (n = 745) 98 (13.2) 1 – –
Yes (n = 19) 2 (10.5) 0.73 (0.18–2.98) – –
Chloroquine/azithromycin–based
treatment
No (n = 96) 28 (29.2) 1 1 –
Yes (n = 630) 69 (11.0) 0.33 (0.21–0.52) 0.26 (0.16–0.42) < 0.001
Received oxygen
No (n = 330) 7 (2.1) 1 – –
Yes (n = 245) 92 (37.6) 21.88 (10.14–47.25) – –
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reported in our DRC pediatric cohort, but it may not have been
recognized. Our study’s small number of children and the
possibility of unmeasured confounding factors, such as the
availability of necessary equipment, quality, and scope of
pediatric intensive care, preclude concrete conclusions about
excess COVID-19–related mortality among children and ad-
olescents in the DRC. This calls for larger, robust investiga-
tions of COVID-19 outcomes among hospitalized children
in SSA.
Our study has some limitations. Approximately 10% of
patients had missing data on outcomes of interest and were
not included in our analysis. However, these patients were
comparable with those included with respect to sociodemo-
graphic characteristics and COVID-19 clinical stage. In addi-
tion, we were not able to compare clinical characteristics
between hospitalized COVID-19 patients and outpatients.
Finally, given the low prevalence of self-reported HIV and/or
TB status, we cannot speculate on the impact of these con-
ditions on COVID-19 outcomes. Strengths of our study in-
clude a robust sample size of hospitalized patients in SSA
fromwhere little information on COVID-19 has been reported.
We also provide data on 34 children, a population for whom
there are even less COVID-19 data available from SSA.9 Fi-
nally, the use of robust statistical methods such as MSM and
IPTWcreatesmorebalancedcomparisonsbetween treatment
groups, similar to those that would be found in a randomized
clinical trial.
CONCLUSION
In this study, hospitalized patients in SSA with COVID-19
had a somewhat lower overall in-hospital mortality than hos-
pitalized patients in non-African regions, butmortality in those
with severe or critical diseasewas almost 50%.Age-groups at
high risk and comorbidities associatedwith deathwere similar
between our cohort and those from prior studies in Asia,
Europe, and North America. Although our study provides in-
sights into COVID-19 manifestations in Africa, more data are
needed from countries across this region. Large-cohort ob-
servational studies are required to better define the epidemi-
ology and factors affecting COVID-19 outcomes and the
relationships between the overlapping epidemics ofCOVID-19,
HIV, TB, andmalaria among both young and older populations.
Rigorous evaluations of promising, scalable, and cost-effective
therapeutics and vaccines are needed globally.
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Kasayi, Kananga, Democratic Republic of the Congo, and Faculty of
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